David Reyes‐Leiva

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Michael Böhm, Kazuomi Kario, David E. Kandzari et al. · The Lancet · 2020 · 555 citations

Antihypertensive Medications, Hypertension, Urology +9

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 124 citations

Clinical Trials, Cipaglucosidase Alfa, Pharmacotherapy +2

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications

David E. Kandzari, Raymond R. Townsend, Kazuomi Kario et al. · Journal of the American College of Cardiology · 2023 · 93 citations

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

Elena Cortés‐Vicente, Rodrigo Álvarez‐Velasco, Francesc Pla‐Juncà et al. · Annals of Clinical and Translational Neurology · 2022 · 51 citations · Full text